Viewing data from:

FEMRING

NDA

ESTRADIOL ACETATE | N021367 | MILLICENT MANUFACTURING PR LLC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 2 NDCs

Highest NADAC/Unit

$925.75

per ea

Lowest NADAC/Unit

$866.31

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
72495020210FEMRING 0.10 MG/DAY VAG RING	$925.75	EA	Brand	—	2026-10-21
72495020105FEMRING 0.05 MG/DAY VAG RING	$866.31	EA	Brand	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 4 NDCs (2 FSS, 2 Big4)

Lowest Price

$558.00

Highest Price

$797.91

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
72495-0201-05FEMRING 0.05MG/24HR RING,VAG	$558.00	Big4	Millicent U.S., Inc.	04/30/2030
72495-0201-05FEMRING 0.05MG/24HR RING,VAG	$748.76	FSS	Millicent U.S., Inc.	04/30/2030
72495-0202-10FEMRING 0.1MG/24HR RING,VAG	$596.48	Big4	Millicent U.S., Inc.	04/30/2030
72495-0202-10FEMRING 0.1MG/24HR RING,VAG	$797.91	FSS	Millicent U.S., Inc.	04/30/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Femring (2024)

Total Spending

$7.0M

Total Claims

9,145

Beneficiaries

3,074

Avg Cost/Unit

$753.54

Spending Trend

$3.5M(2019)→$5.1M(2020)→$5.6M(2021)→$6.0M(2022)→$6.5M(2023)→$7.0M(2024)

YoY Change:+2.4%

5yr CAGR:+9.0%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

11 letters from Drugs@FDA

Date	Submission	Document
Feb 16, 2024	SUPPL -21	View Letter (PDF)
Aug 22, 2023	SUPPL -20	View Letter (PDF)
Nov 7, 2017	SUPPL -16	View Letter (PDF)
Aug 15, 2017	SUPPL -14	View Letter (PDF)
Aug 15, 2017	SUPPL -15	View Letter (PDF)
Jun 2, 2014	SUPPL -13	View Letter (PDF)
May 27, 2009	SUPPL -9	View Letter (PDF)
Feb 23, 2007	SUPPL -7	View Letter (PDF)
Aug 19, 2005	SUPPL -5	View Letter (PDF)
Mar 14, 2005	SUPPL -2	View Letter (PDF)
Mar 26, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 0.05MG BASE/24HR

RLD

0 patents0 exclusivities▴

INSERT, EXTENDED RELEASE;VAGINAL | Approved: Mar 20, 2003

No patent or exclusivity listings for this strength.

#002 — EQ 0.1MG BASE/24HR

RLD

0 patents0 exclusivities▾

INSERT, EXTENDED RELEASE;VAGINAL | Approved: Mar 20, 2003